Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936658 | 0.94 | GFER (0.72) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| SCHEMBL9155140 | 0.93 | GFER (0.61) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| Isovanillin SCHEMBL1936859 | 0.92 | HPGD (0.63) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| SCHEMBL15631695 | 0.85 | GFER (0.53) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| SCHEMBL21993216 | 0.83 | GFER (0.58) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| SCHEMBL222229 | 0.81 | GFER (0.60) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| SCHEMBL222522 | 0.81 | GFER (0.60) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| SCHEMBL222230 | 0.81 | GFER (0.60) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 | |
| SCHEMBL6938287 | 0.81 | GFER (0.54) | HPGDSMN1; SMN2GFERALDH1A1GAA | |
| SCHEMBL9197679 | 0.81 | ALDH1A1 (0.55) | HPGDSMN1; SMN2MAPK1GFERALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735620-B2 | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders | EPR PHARMACEUTICALS PVT. LTD (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-2331539-A2 | 1,3,4,6,7,11B-HEXAHYDRO-BENZO[ALPHA]QUINOLIZINES FOR THE TREATMENT OF HYPERKINETIC MOVEMENT AND RELATED DISORDERS | Biovail Laboratories International (Barbados) SRL (BB) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | EPR PHARMACEUTICALS PVT.LTD | 2010-06-17 | — | — | US | disclosed |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | Biovali Laboratories International (Barbados) S.R.L. (BB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | Biovali Laboratories International (Barbados) S.R.L. (BB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010026436-A2 | PHARMACEUTICAL COMPOUNDS | BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) SRL (BB) | 2010-03-11 | — | — | WO | disclosed |
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2002-06-06 | — | — | US | disclosed |
| EP-0819122-B1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
| EP-0819122-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031485-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | HRH2, CBR1, HRH1 | HPGD 255/4885SMN1; SMN2 2626/4885MAPK1 1254/4885 |
| US-20100152491-A1 | PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS | PCNA, CDC25B, CCNB1 | HPGD 826/4885SMN1; SMN2 1400/4885MAPK1 1525/4885 |
| US-20100087475-A1 | PHARMACEUTICAL COMPOUNDS | UGT2B7, CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HPGD 363/4885SMN1; SMN2 3277/4885MAPK1 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.